ABL Diagnostics
ABLD
Company Profile
Business description
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
Contact
72c, rue de, WOIPPY
Thionville57140
FRAT: +33 783646850
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,078.20 | 49.40 | 0.55% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,905.39 | 2.86 | 0.01% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,655.37 | 105.83 | 0.26% |
| NZX 50 Index | 12,888.01 | 10.97 | 0.09% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,812.60 | 42.20 | 0.48% |
| SSE Composite Index | 3,619.66 | 2.06 | 0.06% |